EA201201362A1 - PHARMACEUTICAL AEROSOL COMPOSITION PROTEASIS INHIBITORS AND ITS OBTAINING - Google Patents

PHARMACEUTICAL AEROSOL COMPOSITION PROTEASIS INHIBITORS AND ITS OBTAINING

Info

Publication number
EA201201362A1
EA201201362A1 EA201201362A EA201201362A EA201201362A1 EA 201201362 A1 EA201201362 A1 EA 201201362A1 EA 201201362 A EA201201362 A EA 201201362A EA 201201362 A EA201201362 A EA 201201362A EA 201201362 A1 EA201201362 A1 EA 201201362A1
Authority
EA
Eurasian Patent Office
Prior art keywords
aerosol
inhibitors
proteasis
obtaining
aerosol composition
Prior art date
Application number
EA201201362A
Other languages
Russian (ru)
Other versions
EA034991B1 (en
Inventor
Олег Петрович ЖИРНОВ
Original Assignee
Олег Петрович ЖИРНОВ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Олег Петрович ЖИРНОВ filed Critical Олег Петрович ЖИРНОВ
Publication of EA201201362A1 publication Critical patent/EA201201362A1/en
Publication of EA034991B1 publication Critical patent/EA034991B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к медицине и описывает лекарственную композицию водорастворимых белковых или полипептидных соединений из группы ингибиторов протеолитических ферментов для создания аэрозоля с помощью водонерастворимого озонсберегающего пропеллента в аэрозольных устройствах, снабженных дозирующим клапаном. Созданный аэрозольный состав может найти применение при лечении заболеваний, сопровождающихся нарушением протеолитического баланса, таких как респираторные инфекции, включая грипп, кератоконъюнктивиты вирусной и бактериальной этиологии, герпетические поражения слизистых оболочек и кожи, хроническая обструктивная бронхопневмония, астма и др.The invention relates to medicine and describes a medicinal composition of water-soluble protein or polypeptide compounds from the group of proteolytic enzyme inhibitors to create an aerosol using a water-insoluble ozone-saving propellant in aerosol devices equipped with a metering valve. The created aerosol composition can be used in the treatment of diseases accompanied by a violation of the proteolytic balance, such as respiratory infections, including influenza, keratoconjunctivitis of viral and bacterial etiology, herpetic lesions of the mucous membranes and skin, chronic obstructive bronchopneumonia, asthma, etc.

EA201201362A 2011-11-03 2012-10-27 Pharmaceutical aerosol formulation of a protease inhibitor EA034991B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2011144624A RU2657523C2 (en) 2011-11-03 2011-11-03 Pharmaceutical aerosol composition of protease inhibitors with ozone-preserving propellant and its preparation

Publications (2)

Publication Number Publication Date
EA201201362A1 true EA201201362A1 (en) 2013-05-30
EA034991B1 EA034991B1 (en) 2020-04-15

Family

ID=48192963

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201362A EA034991B1 (en) 2011-11-03 2012-10-27 Pharmaceutical aerosol formulation of a protease inhibitor

Country Status (4)

Country Link
EA (1) EA034991B1 (en)
GB (1) GB2511011A (en)
RU (1) RU2657523C2 (en)
WO (1) WO2013066214A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2711080C2 (en) * 2015-06-15 2020-01-15 Олег Петрович Жирнов Combined aerosol composition based on protease inhibitors and preparation thereof
WO2022216172A1 (en) * 2021-04-06 2022-10-13 Андрей Александрович ИВАЩЕНКО Aqueous aprotinin-containing antiviral pharmaceutical composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2656944B2 (en) * 1987-04-30 1997-09-24 クーパー ラボラトリーズ Aerosolization of protein therapeutics
RU2054180C1 (en) * 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Method and aerosol for treating respiratory virus infections
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US6294153B1 (en) * 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
AU5936400A (en) * 1999-06-04 2000-12-28 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
EP1343521A2 (en) * 2000-12-01 2003-09-17 Battelle Memorial Institute Method for the stabilizing biomolecules (e.g. insulin) in liquid formulations
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
RU2356537C2 (en) * 2007-07-25 2009-05-27 Закрытое Акционерное Общество (ЗАО) "Пульмомед" Pharmaceutical composition of metered aerosols containing antiasthmatic agents in form of suspensions, solutions, emulsions, solutions and emulsions
RU2425691C1 (en) * 2010-07-15 2011-08-10 ВАКЕ спол с.р.о. Aprotinin aerosol for treating viral respiratory infections

Also Published As

Publication number Publication date
WO2013066214A3 (en) 2013-08-22
RU2657523C2 (en) 2018-06-14
EA034991B1 (en) 2020-04-15
RU2011144624A (en) 2013-05-10
GB201409877D0 (en) 2014-07-16
WO2013066214A2 (en) 2013-05-10
GB2511011A (en) 2014-08-20

Similar Documents

Publication Publication Date Title
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
BR112015007366A2 (en) acylaminopyrimidine derivatives for the treatment of viral infections and other diseases
BR112014007223A2 (en) estra-1,3,5 (10), 16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments
EA201690541A1 (en) DRY POWDER PREPARATION CONTAINING PHOSPHODESTERASE INHIBITOR
CL2014000122A1 (en) Compounds derived from indazole, janus kinase inhibitors (jak); pharmaceutical composition that includes them; and its use to treat allergic rhinitis, nasal congestion, asthma, chronic bronchitis, arthritis, heart failure, ulcerative colitis, viral and bacterial infection, cancer and Alzheimer's, among other diseases.
PH12020551709A1 (en) Antiviral immunotropic agent for the treatment of acute respiratory viral infections
JP2015534562A5 (en)
BR112014015845A2 (en) azetidine derivatives, pharmaceutical compositions and their use
EA201391719A1 (en) HINASOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES
BR112014027681A2 (en) hydrophobic therapeutic preparations, methods of manufacture and use thereof
CO6280490A2 (en) 4- (4-CIANO-2-TIOARIL) DIHYDROPIRIMIDINONES AND ITS USE
BR112014007694A2 (en) 1-pyrazolyl-3- (4 - ((2-anilinopyrimidin-4-yl) oxy) naphthalen-1-yl) ureas as p38 map kinase inhibitors
BR112014031291A2 (en) metered valve for dispensing
CL2012001836A1 (en) Pyrazole compounds, crth2 antagonist; pharmaceutical composition; use in the treatment of inflammatory, infectious, immunoregulatory disorders, respiratory diseases, gastrointestinal or ailments, among others.
BR112014018953A8 (en) TRITERPENOID LUPANE DERIVATIVES AND PHARMACEUTICAL USE THEREOF
GB2503066A8 (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
BR112014011345A2 (en) influenza virus-like particles (vlps) comprising nicotiana tabacum produced by hemagglutinin
NZ631105A (en) Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
Li et al. Cappariloside A shows antiviral and better anti-inflammatory effects against influenza virus via regulating host IFN signaling, in vitro and vivo
BR112014005538A2 (en) aqueous compositions comprising arbecacin
EA201201362A1 (en) PHARMACEUTICAL AEROSOL COMPOSITION PROTEASIS INHIBITORS AND ITS OBTAINING
PH12018502522A1 (en) Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
EA201591415A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING MULTICOMPONENT CRYSTALLINE PARTICLES, SUITABLE FOR USE IN INHALATION THERAPY
BR112015028890A2 (en) Pyridone derivatives for the treatment of viral infections and other diseases
BR112014007491A2 (en) amino acid sequences for pathogen control

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): TJ TM